However, the impact of these variants on chemotherapy response may be negligible because renal carcinoma expresses low OCT2 levels compared to normal kidney tissue[89], and the antitumor drugs described as OCT2-substrates (ifosfamide and platinum derivatives)[85,90] are not used in the treatment of renal carcinoma. Here, SLC22A2 is linked to renal carcinoma.